Treatment options for localized prostate cancer.
暂无分享,去创建一个
Nawaid Usmani | Mira Keyes | W James Morris | Gerard Morton | Eric Vigneault | W. J. Morris | M. Keyes | É. Vigneault | J. Crook | N. Usmani | G. Morton | Juanita Crook | W. Morris
[1] Deb Feldman-Stewart,et al. The Impact of Explicit Values Clarification Exercises in a Patient Decision Aid Emerges After the Decision Is Actually Made , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[2]
G. Lockwood,et al.
Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged
[3] François Harel,et al. Évolution clinique des patients atteints d’un cancer prostatique de risque intermédiaire traités par implants permanents d’iode-125 : l’expérience de l’Hôtel-Dieu de Québec , 2010 .
[4] D. Engeler,et al. Health-Related Quality of Life after Radical Prostatectomy and Low-Dose-Rate Brachytherapy for Localized Prostate Cancer , 2009, Urologia Internationalis.
[5] John T. Wei,et al. Prediction of erectile function following treatment for prostate cancer. , 2011, JAMA.
[6] D. Grignon,et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.
[7] M. Kattan,et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. , 2008, The Journal of urology.
[8] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[9] Jean Pouliot,et al. Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience. , 2007, International journal of radiation oncology, biology, physics.
[10] Lei Dong,et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[11] Jacques Bernier,et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.
[12] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[13] C. Begg,et al. Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. , 2005, The Journal of urology.
[14] J. Chin,et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. , 2003, The Journal of urology.
[15] C. L. Cutajar,et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. , 2010, The Lancet. Oncology.
[16] Howard Pai,et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. , 2009, International journal of radiation oncology, biology, physics.
[17] A. Briganti,et al. Erectile function rehabilitation in the radical prostatectomy patient. , 2010, The journal of sexual medicine.
[18] M. Kattan,et al. Risk factors for urinary incontinence after radical prostatectomy. , 1996, The Journal of urology.
[19] J. Robinson,et al. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. , 2002, International journal of radiation oncology, biology, physics.
[20] Ola Svenson,et al. Patient‐focussed decision‐making in early‐stage prostate cancer: insights from a cognitively based decision aid , 2004, Health expectations : an international journal of public participation in health care and health policy.
[21] Angela Mariotto,et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.
[22] C. Roehrborn,et al. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] G. Pond,et al. Long-term urinary sequelae following 125iodine prostate brachytherapy. , 2008, The Journal of urology.
[24] R. Stock,et al. Effect of low dose‐rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at ≥ 7 years of follow‐up , 2007, BJU international.
[25] M. Morrow,et al. Results of hospital cancer registry surveys by the American College of Surgeons , 1997, Cancer.
[26] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[27] L Souhami,et al. Controversies in prostate cancer radiotherapy: consensus development. , 2001, The Canadian journal of urology.
[28] Grace A Lin,et al. Patient Decision Aids for Prostate Cancer Treatment: A Systematic Review of the Literature , 2009, CA: a cancer journal for clinicians.
[29] W. J. Morris,et al. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis. , 2010, International journal of radiation oncology, biology, physics.
[30] C. Giberti,et al. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study , 2009, World Journal of Urology.
[31] W. J. Morris,et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. , 2009, Urology.
[32] J. Trachtenberg,et al. Does nerve-sparing radical prostatectomy increase the risk of positive surgical margins and biochemical progression? , 2010, Urology annals.
[33] Howard Pai,et al. Rectal toxicity and rectal dosimetry in low-dose-rate (125)I permanent prostate implants: a long-term study in 1006 patients. , 2012, Brachytherapy.
[34] P. Walsh,et al. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. , 2000, Urology.
[35] R A Stephenson,et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.
[36] L. Lacombe,et al. Substratification of high-risk localised prostate cancer treated by radical prostatectomy , 2008, World Journal of Urology.
[37] John T. Wei,et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.
[38] Alexandre Mamedov,et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Crook,et al. Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Lisa M. Schwartz,et al. Numbers needed to decide. , 2009, Journal of the National Cancer Institute.
[41] Adam P Dicker,et al. Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group , 2012, BJU international.
[42] Jette Borg,et al. 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients. , 2011, International journal of radiation oncology, biology, physics.
[43] L. Sobin,et al. TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.
[44] W. Catalona,et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. , 2004, The Journal of urology.